Regional and Sex-Specific Alterations in the Visual Cortex of Individuals With Psychosis Spectrum Disorders.


Journal

Biological psychiatry
ISSN: 1873-2402
Titre abrégé: Biol Psychiatry
Pays: United States
ID NLM: 0213264

Informations de publication

Date de publication:
01 09 2022
Historique:
received: 04 11 2021
revised: 10 03 2022
accepted: 29 03 2022
pubmed: 11 6 2022
medline: 16 8 2022
entrez: 10 6 2022
Statut: ppublish

Résumé

Impairments of the visual system are implicated in psychotic disorders. However, studies exploring visual cortex (VC) morphology in this population are limited. Using data from the Bipolar-Schizophrenia Network on Intermediate Phenotypes consortium, we examined VC structure in psychosis probands and their first-degree relatives (RELs), sex differences in VC measures, and their relationships with cognitive and peripheral inflammatory markers. Cortical thickness, surface area, and volume of the primary (Brodmann area 17/V1) and secondary (Brodmann area 18/V2) visual areas and the middle temporal (V5/MT) region were quantified using FreeSurfer version 6.0 in psychosis probands (n = 530), first-degree RELs (n = 544), and healthy control subjects (n = 323). Familiality estimates were determined for probands and RELs. General cognition, response inhibition, and emotion recognition functions were assessed. Systemic inflammation was measured in a subset of participants. Psychosis probands demonstrated significant area, thickness, and volume reductions in V1, V2, and MT, and their first-degree RELs demonstrated area and volume reductions in MT compared with control subjects. There was a higher degree of familiality for VC area than thickness. Area and volume reductions in V1 and V2 were sex dependent, affecting only female probands in a regionally specific manner. Reductions in some VC regions were correlated with poor general cognition, worse response inhibition, and increased C-reactive protein levels. The visual cortex is a site of significant pathology in psychotic disorders, with distinct patterns of area and thickness changes, sex-specific and regional effects, potential contributions to cognitive impairments, and association with C-reactive protein levels.

Sections du résumé

BACKGROUND
Impairments of the visual system are implicated in psychotic disorders. However, studies exploring visual cortex (VC) morphology in this population are limited. Using data from the Bipolar-Schizophrenia Network on Intermediate Phenotypes consortium, we examined VC structure in psychosis probands and their first-degree relatives (RELs), sex differences in VC measures, and their relationships with cognitive and peripheral inflammatory markers.
METHODS
Cortical thickness, surface area, and volume of the primary (Brodmann area 17/V1) and secondary (Brodmann area 18/V2) visual areas and the middle temporal (V5/MT) region were quantified using FreeSurfer version 6.0 in psychosis probands (n = 530), first-degree RELs (n = 544), and healthy control subjects (n = 323). Familiality estimates were determined for probands and RELs. General cognition, response inhibition, and emotion recognition functions were assessed. Systemic inflammation was measured in a subset of participants.
RESULTS
Psychosis probands demonstrated significant area, thickness, and volume reductions in V1, V2, and MT, and their first-degree RELs demonstrated area and volume reductions in MT compared with control subjects. There was a higher degree of familiality for VC area than thickness. Area and volume reductions in V1 and V2 were sex dependent, affecting only female probands in a regionally specific manner. Reductions in some VC regions were correlated with poor general cognition, worse response inhibition, and increased C-reactive protein levels.
CONCLUSIONS
The visual cortex is a site of significant pathology in psychotic disorders, with distinct patterns of area and thickness changes, sex-specific and regional effects, potential contributions to cognitive impairments, and association with C-reactive protein levels.

Identifiants

pubmed: 35688762
pii: S0006-3223(22)01159-3
doi: 10.1016/j.biopsych.2022.03.023
pii:
doi:

Substances chimiques

C-Reactive Protein 9007-41-4

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-406

Subventions

Organisme : NIMH NIH HHS
ID : R25 MH101078
Pays : United States
Organisme : NCATS NIH HHS
ID : KL2 TR002542
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000114
Pays : United States

Informations de copyright

Copyright © 2022 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Auteurs

Halide Bilge Türközer (HB)

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas; Division of Child and Adolescent Psychiatry, Massachusetts General Hospital and McLean Hospital, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. Electronic address: bilge.turkozer@gmail.com.

Paulo Lizano (P)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts. Electronic address: lizanopl@gmail.com.

Iniya Adhan (I)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts.

Elena I Ivleva (EI)

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.

Olivia Lutz (O)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts.

Victor Zeng (V)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts.

Alexandria Zeng (A)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts.

Nicholas Raymond (N)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts.

Deepthi Bannai (D)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts.

Adam Lee (A)

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota.

Jeffrey R Bishop (JR)

Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota; Department of Psychiatry and Behavioral Sciences, Medical School, University of Minnesota, Minneapolis, Minnesota.

Brett A Clementz (BA)

Departments of Psychology and Neuroscience, Bio-Imaging Research Center, University of Georgia, Athens, Georgia.

Godfrey D Pearlson (GD)

Olin Neuropsychiatry Research Center/Institute of Living, Hartford Hospital, Hartford; Departments of Psychiatry and Neuroscience, Yale University, New Haven, Connecticut.

John A Sweeney (JA)

Department of Psychiatry, University of Cincinnati, Cincinnati, Ohio.

Elliot S Gershon (ES)

Department of Psychiatry, University of Chicago, Chicago, Illinois.

Matcheri S Keshavan (MS)

Department of Psychiatry, Beth Israel Deaconess Medical Center and Massachusetts Mental Health Center, Boston, Massachusetts; Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.

Carol A Tamminga (CA)

Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH